Insmed (INSM) Change in Cash (2010 - 2026)
Insmed (INSM) posted quarterly Change in Cash of $71.7 million for Q1 2026, up 147.27% year-over-year from $29.0 million in Q1 2025, and down 59.16% quarter-over-quarter from $175.7 million in Q4 2025.
Insmed (INSM) Change in Cash (2010 - 2026) Analysis & Trends
Insmed's Change in Cash history runs 17 years deep, the most recent figure standing at $71.7 million for Q1 2026.
- In Q1 2026, Change in Cash rose 147.27% year-over-year to $71.7 million; the TTM figure through Mar 2026 stood at $178.9 million (up 192.97% YoY), while the FY2025 annual figure was -$44.6 million, down 161.36% from the prior year.
- Change in Cash for Q1 2026 stood at $71.7 million, down from $175.7 million in the prior quarter.
- The five-year high for Change in Cash was $881.1 million in Q2 2025, with the low at -$949.6 million in Q3 2025.
- The 5-year median for Change in Cash is -$4.7 million (2023), against an average of -$7.9 million.
- The sharpest annual moves came in 2023 and 2024: Change in Cash slumped 8603.74% in 2023, then surged 2074.66% in 2024.
- Insmed's Change in Cash stood at $659.4 million in 2022, then tumbled by 100.72% to -$4.7 million in 2023, then soared by 2074.66% to $93.6 million in 2024, then surged by 87.74% to $175.7 million in 2025, then slumped by 59.16% to $71.7 million in 2026.
- Business Quant data shows INSM's Change in Cash at $71.7 million in Q1 2026, $175.7 million in Q4 2025, and -$949.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 427.25 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.97 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.94 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -170.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.42 Mn |
| Mar 31, 2026 | 71.74 Mn |
| Dec 31, 2025 | 175.68 Mn |
| Sep 30, 2025 | -949.56 Mn |
| Jun 30, 2025 | 881.08 Mn |
| Mar 31, 2025 | -151.78 Mn |
| Dec 31, 2024 | 93.58 Mn |
| Sep 30, 2024 | -785.35 Mn |
| Jun 30, 2024 | 651.07 Mn |
| Mar 31, 2024 | 113.36 Mn |
| Dec 31, 2023 | -4.74 Mn |
| Sep 30, 2023 | -125.77 Mn |
| Jun 30, 2023 | -356.03 Mn |
| Mar 31, 2023 | -105.13 Mn |
| Dec 31, 2022 | 659.40 Mn |
| Sep 30, 2022 | -1.45 Mn |
| Jun 30, 2022 | -99.63 Mn |
| Mar 31, 2022 | -201.08 Mn |
| Dec 31, 2021 | -129.77 Mn |
| Sep 30, 2021 | -81.77 Mn |